Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Cipla with MYLAN INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

CIPLA vs MYLAN (US) - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More


Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More



5-Yr Chart
Click to enlarge
High Rs6634,285-   
Low Rs4793,019-   
Sales per share (Unadj.) Rs189.01,466.8-  
Earnings per share (Unadj.) Rs17.6176.7-  
Cash flow per share (Unadj.) Rs34.0284.4-  
Dividends per share (Unadj.) Rs3.000-  
Dividend yield (eoy) %0.50-  
Book value per share (Unadj.) Rs176.7729.1-  
Shares outstanding (eoy) m805.12378.37-   
Bonus/Rights/Conversions ESOPOI-  
Price / Sales ratio x3.02.5 121.3%   
Avg P/E ratio x32.520.7 157.0%  
P/CF ratio (eoy) x16.812.8 130.7%  
Price / Book Value ratio x3.25.0 64.5%  
Dividend payout %17.10-   
Avg Mkt Cap Rs m459,7241,381,812 33.3%   
No. of employees `00023.625.0 94.4%   
Total wages/salary Rs m26,9010-   
Avg. sales/employee Rs Th6,446.122,199.6 29.0%   
Avg. wages/employee Rs Th1,139.40-   
Avg. net profit/employee Rs Th600.02,674.3 22.4%   
Net Sales Rs m152,193554,991 27.4%  
Other income Rs m3,577-3,235 -110.6%   
Total revenues Rs m155,769551,756 28.2%   
Gross profit Rs m28,264138,029 20.5%  
Depreciation Rs m13,22840,762 32.5%   
Interest Rs m1,14223,939 4.8%   
Profit before tax Rs m17,47070,093 24.9%   
Minority Interest Rs m0-288 0.0%   
Prior Period Items Rs m-280-   
Extraordinary Inc (Exp) Rs m-7750-   
Tax Rs m2,5012,947 84.9%   
Profit after tax Rs m14,16666,858 21.2%  
Gross profit margin %18.624.9 74.7%  
Effective tax rate %14.34.2 340.5%   
Net profit margin %9.312.0 77.3%  
Current assets Rs m108,141487,910 22.2%   
Current liabilities Rs m38,322381,448 10.0%   
Net working cap to sales %45.919.2 239.2%  
Current ratio x2.81.3 220.6%  
Inventory Days Days9778 124.3%  
Debtors Days Days74107 69.4%  
Net fixed assets Rs m109,411128,396 85.2%   
Share capital Rs m1,61019,626 8.2%   
"Free" reserves Rs m140,6820-   
Net worth Rs m142,292275,885 51.6%   
Long term debt Rs m36,621412,145 8.9%   
Total assets Rs m228,6061,111,240 20.6%  
Interest coverage x16.33.9 414.8%   
Debt to equity ratio x0.31.5 17.2%  
Sales to assets ratio x0.70.5 133.3%   
Return on assets %6.78.2 82.0%  
Return on equity %10.024.2 41.1%  
Return on capital %10.013.6 73.1%  
Exports to sales %32.80-   
Imports to sales %00-   
Net fx Rs m30,6580-   
From Operations Rs m14,62872,954 20.1%  
From Investments Rs m-8,540-57,534 14.8%  
From Financial Activity Rs m-3,855-19,223 20.1%  
Net Cashflow Rs m2,431-3,803 -63.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 71.89 Rs / USD

Compare CIPLA With: ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  


Today's Market

Indian Indices End Week Strong, Pharma Stocks Show Uptick(Pre-Open)

On Friday, share markets in India opened on a positive note and ended the day in green after a volatile day of trading.

Related Views On News

CIPLA Announces Quarterly Results (2QFY19); Net Profit Down 15.8% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, CIPLA has posted a net profit of Rs 4 bn (down 15.8% YoY). Sales on the other hand came in at Rs 40 bn (down 1.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (1QFY19); Net Profit Up 4.7% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, CIPLA has posted a net profit of Rs 4 bn (up 4.7% YoY). Sales on the other hand came in at Rs 39 bn (up 11.7% YoY). Read on for a complete analysis of CIPLA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Get this Small Cap Logistics Company at a 16% Discount Right Now...(Profit Hunter)

Nov 6, 2018

If you turn the clock back, the current macroeconomic climate is nothing new. The markets have seen them all, and every downcycle has been succeeded by gravity defying gains...more so in the small cap space. This time will be no different.

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

Does it Make Sense to Invest in Offshore Funds?(Outside View)

Nov 6, 2018

Many investors prefer to invest in offshore funds because of the rupee depreciation and on-going downtrend in the markets, but it is to be invested only when there is no option available to invest in India.


Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Nov 16, 2018 (Close)